Compugen (NASDAQ:CGEN) Upgraded by StockNews.com to “Buy”

StockNews.com upgraded shares of Compugen (NASDAQ:CGEN) from a hold rating to a buy rating in a research note issued to investors on Thursday morning.

Separately, Truist Financial dropped their target price on shares of Compugen from $5.00 to $4.00 and set a buy rating on the stock in a report on Tuesday, May 21st.

Compugen Stock Up 0.6 %

Shares of CGEN stock opened at $1.76 on Thursday. Compugen has a 12-month low of $0.53 and a 12-month high of $3.03. The firm has a fifty day moving average of $2.06 and a 200-day moving average of $2.12. The firm has a market capitalization of $152.46 million, a price-to-earnings ratio of -9.26 and a beta of 2.71.

Compugen (NASDAQ:CGEN) last posted its earnings results on Monday, May 20th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02. The business had revenue of $2.56 million during the quarter, compared to analyst estimates of $2.79 million. Research analysts expect that Compugen will post 0.05 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Compugen stock. Heron Bay Capital Management purchased a new position in shares of Compugen Ltd. (NASDAQ:CGEN) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 12,547 shares of the biotechnology company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.